Pfizer Centers for Therapeutic Innovation
We are pleased to alert you to the call for proposals for Pfizer’s Centers for Therapeutic Innovation (CTI) program for collaborative development of novel biotherapeutics.
CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, and Internal Medicine.
Key elements are summarized below and the final submission deadline to Innovation for review is June 21, 2021. Similar to last year, CTI will have only 1 CFP cycle which will be open until late June. Investigators are encouraged to submit whenever they have a proposal ready. Pre-proposals submitted within the timeframe outlined below will be reviewed on a rolling basis.
Deadline to submit pre-proposal to Innovation: Monday, June 21, 2021.
Innovation Fellows Program
The Innovation Fellows Program is a new initiative that seeks to increase collaboration between the Mass General Brigham community and industry. It is an opportunity for a personnel exchange between Mass General Brigham core hospitals – Brigham and Women’s Hospital, Massachusetts General Hospital, and McLean Hospital – and participating biopharmaceuticals, venture capital firms, and other commercial entities.
Call for Brief Proposal Summaries: Deadline May 24, 2021
We are pleased to announce the seventh annual call for pre-proposals for the Sanofi iAwards Program, which aims to fund innovative and translational research ideas that can contribute to our early stage pipeline and ultimately benefit patients
The iAwards program provides $125,000 in research funding for a one-year study, and successful projects have the potential to grow into sponsored research agreements with significantly increased funding and timelines. Over the past 6 years, 24 projects have been funded at BWH and MGH across a diverse range of therapeutic areas.
Innovation Discovery Grants
The Innovation Discovery Grants (IDG) program aims to enhance the commercial outcomes of the Mass General Brigham community and to increase its innovative potential. It is designed to stimulate new inventive concepts, identify areas of commercially significant scientific strength, and accelerate commercialization of Mass General Brigham intellectual assets. The IDG program will fund projects that can demonstrate tangible outcomes towards commercialization licensing opportunities, or a spin-off company, based on a drug, device, diagnostic, healthcare IT, or other product or service that improves patient health or healthcare delivery.